Key facts
- Notable investors include Blue Valley Fund One, VentureSouth.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Adovate
- ·The full record, as it builds
Funding rounds
No funding rounds for Adovate are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Adovate
Operator of an adenosine drug development platform intended to create novel therapeutics targeting adenosine receptors involved in major diseases. The company specializes in designing patented compounds with favorable physicochemical characteristics and optimized distribution kinetics that overcome historical limitations of adenosine receptor-targeting drugs, enabling doctors to advance previously challenging therapeutic targets into viable treatment options.
- Sector
- Healthcare
- HQ
- Charlottesville, VA, United States
- Founded
- 2023
- Employees
- 22
- Website
- adovate.com/
- Ownership
- Privately Held (backing)
Adovate doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Adovate shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Adovate in its N-PORT filings yet. We sweep new filings monthly.